Wang Z, Ma L, Xu J, Jiang C
Front Cell Dev Biol. 2024; 12:1519539.
PMID: 39717843
PMC: 11663938.
DOI: 10.3389/fcell.2024.1519539.
Andolino C, Cotul E, Xianyu Z, Li Y, Bhat D, Ayers M
Res Sq. 2024; .
PMID: 39678343
PMC: 11643320.
DOI: 10.21203/rs.3.rs-5510550/v1.
Sui L, Wang J, Jiang W, Song X, Ye L
Front Oncol. 2024; 14:1401113.
PMID: 39605887
PMC: 11599183.
DOI: 10.3389/fonc.2024.1401113.
Guder C, Heinrich S, Seifert-Klauss V, Kiechle M, Bauer L, Ollinger R
Int J Mol Sci. 2024; 25(21).
PMID: 39519195
PMC: 11546379.
DOI: 10.3390/ijms252111643.
Biesok M, Juszczyk J, Badura P
Sci Rep. 2024; 14(1):25859.
PMID: 39468220
PMC: 11519628.
DOI: 10.1038/s41598-024-76308-x.
Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application.
Su L, Bu J, Yu J, Jin M, Meng G, Zhu X
Clin Transl Med. 2024; 14(11):e70066.
PMID: 39462685
PMC: 11513202.
DOI: 10.1002/ctm2.70066.
Tumor-intrinsic role of ICAM-1 in driving metastatic progression of triple-negative breast cancer through direct interaction with EGFR.
Kang J, Uddin N, Kim S, Zhao Y, Yoo K, Kim M
Mol Cancer. 2024; 23(1):230.
PMID: 39415210
PMC: 11481280.
DOI: 10.1186/s12943-024-02150-4.
Neratinib safety evaluation: real-world adverse event analysis from the FAERS database.
Fan Y, Wu T, Xu P, Yang C, An J, Zhang H
Front Pharmacol. 2024; 15:1425171.
PMID: 39346561
PMC: 11427278.
DOI: 10.3389/fphar.2024.1425171.
Mutational spectrum of breast cancer by shallow whole-genome sequencing of cfDNA and tumor gene panel analysis.
Ambriz-Barrera F, Rojas-Jimenez E, Diaz-Velasquez C, De-La-Cruz-Montoya A, Martinez-Gregorio H, Ruiz-De-La-Cruz M
PLoS One. 2024; 19(9):e0308176.
PMID: 39264897
PMC: 11392417.
DOI: 10.1371/journal.pone.0308176.
Short-Term Exposure to Foodborne Xenoestrogens Affects Breast Cancer Cell Morphology and Motility Relevant for Metastatic Behavior .
Del Favero G, Bergen J, Palm L, Fellinger C, Matlaeva M, Szabadi A
Chem Res Toxicol. 2024; 37(10):1634-1650.
PMID: 39262136
PMC: 11497359.
DOI: 10.1021/acs.chemrestox.4c00061.
Development and Characterization of a Peptide-Bisphosphonate Nanoparticle for the Treatment of Breast Cancer.
Glass K, Fines C, Coulter P, Jena L, McCarthy H, Buckley N
Mol Pharm. 2024; 21(10):4970-4982.
PMID: 39196792
PMC: 11462496.
DOI: 10.1021/acs.molpharmaceut.4c00299.
Digital droplet PCR analysis of organoids generated from mouse mammary tumors demonstrates proof-of-concept capture of tumor heterogeneity.
Lake K, Colonnetta M, Smith C, Saunders K, Martinez-Algarin K, Mohta S
Front Cell Dev Biol. 2024; 12:1358583.
PMID: 38827528
PMC: 11140600.
DOI: 10.3389/fcell.2024.1358583.
Pleiotrophin serum level and metastasis occurrence in breast cancer patients.
Ikhlas M, Ferianto D, Syamsu S, Ganda I, Smaradania N, Sampepajung E
Breast Dis. 2024; 43(1):93-98.
PMID: 38701136
PMC: 11091641.
DOI: 10.3233/BD-249003.
Effects of combined use of ribociclib with PARP1 inhibitor on cell kinetics in breast cancer.
Pulat E, Topcul M
Oncol Lett. 2024; 27(6):243.
PMID: 38638847
PMC: 11024784.
DOI: 10.3892/ol.2024.14376.
Radioactive Seed Localization for Nonpalpable Breast Lesions: Systematic Review and Meta-Analysis.
Ferreira H, de Souza C, Pozzo L, Ribeiro M, Rostelato M
Diagnostics (Basel). 2024; 14(4).
PMID: 38396480
PMC: 10887864.
DOI: 10.3390/diagnostics14040441.
Peroxiredoxin 3 regulates breast cancer progression via ERK-mediated MMP-1 expression.
Chua P, Ow S, Ng C, Huang W, Low J, Tan P
Cancer Cell Int. 2024; 24(1):59.
PMID: 38321552
PMC: 10845805.
DOI: 10.1186/s12935-024-03248-x.
Engl. & Diels (Annonaceae) inhibitory and cytotoxic effects on breast adenocarcinoma growth both and .
Nkuimi O, Silihe K, Tabi Y, Ngo Pambe J, Njamen D, Zingue S
Heliyon. 2024; 10(3):e24410.
PMID: 38317996
PMC: 10839804.
DOI: 10.1016/j.heliyon.2024.e24410.
Prognostic significance and expression pattern of glucose related genes in breast cancer: A comprehensive computational biology approach.
Alshehri B
Saudi J Biol Sci. 2024; 31(1):103896.
PMID: 38173442
PMC: 10761912.
DOI: 10.1016/j.sjbs.2023.103896.
Myosin 1e deficiency affects migration of 4T1 breast cancer cells.
Garone M, Chase S, Zhang C, Krendel M
Cytoskeleton (Hoboken). 2023; 81(12):723-736.
PMID: 38140937
PMC: 11193843.
DOI: 10.1002/cm.21819.
New insights into the correlations between circulating tumor cells and target organ metastasis.
Zhan Q, Liu B, Situ X, Luo Y, Fu T, Wang Y
Signal Transduct Target Ther. 2023; 8(1):465.
PMID: 38129401
PMC: 10739776.
DOI: 10.1038/s41392-023-01725-9.